课题基金 / 基金详情

Analysis of the function of TM4SF complex and its application of lung cancer therapy.

Analysis of the function of TM4SF complex and its application of lung cancer therapy.
TM4SF复合物的功能分析及其在肺癌治疗中的应用
批准号:
16390400
负责人:
MIYAKE Masayuki
金额:
$8.0万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2004
资助国家:
日本
项目状态:
已结题
起止时间:
2004 至 2005

项目摘要

项目成果

MIYAKE Masayuki的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Previously, we found that MRP-1/CD9, a member of the tetraspanin family, suppressed cell motility and metastatic potential to lungs. Moreover, reduction of MRP-1/CD9 gene expression was found to be a factor of a poor prognosis for the patients with non-small cell lung cancer, as was another member of TM4SF, KAI1/CD82. On the other hand, CD151 is identical to an exciting gene PETA-3 which may promote tumor metastasis of malignant cells and its expression may be involved in the malignant progression cancer. We have established various stages of lung cancer cell lines and investigated the complex between tetraspsnin family members and integrin family members. Especially, the complex formation of MRP-1/CD9, KAI1/CD82 and PETA3/CD151 were analyzed. In the Stage I, MRP-1/CD9 and KAI1/CD82 expression were found in two cell lines except one, but PETA3/CD151 appeared weak expression. In the Stage II, KAI1/CD82 was decreasing in 5 cases and MRP-1/CD9 was decreasing in 1 case, however PETA3/CD151 was increasing in 2 cases. In the StageIII, only KAI1/CD82was found decreasing in 4 cases. Then only PETA3/CD151 was appeared in the last 1case. In the StageIV, expression of PETA3/CD151 was positive in almost all metastatic cell lines. From these experiments, MRP-1/CD9 and KAI1/CD82 play an important role as metastasis suppressor genes. On the other hand, PETA3/CD151 plays a metastasis promotion gene. Hence, the balance and unbalance of these expressions have something to do with the process of 'metastasis. Besides, we have found that MRP-1/CD9 and KAI1/CD82 regulate VEGF-A gene and Wnt-1 gene. In addition, we have established the monoclonal antibody recognizing MRP-1/CD9-integrin α3 complex. Using this antibody, we will be able to analyze the mechanism of this complex.
期刊论文(38)
专著(0)
科研奖励(0)
会议论文
Frontiers in Immuno-gene Therapy
免疫基因治疗的前沿
DOI: --
发表时间: 2004
期刊:
影响因子: --
作者: [Hattori, N., Miyake, M.]
通讯作者: M.
呼吸器外科の最新医療
呼吸外科最新医疗护理
DOI: --
发表时间: 2004
期刊:
影响因子: --
作者: [田畑俊治, 岡田克典, 近藤 丘, 岡田克典]
通讯作者: 岡田克典
DOI: --
发表时间: 2005
期刊: 外科治療 93
影响因子: --
作者: [徳原孝洋, 三宅正幸]
通讯作者: 三宅正幸
Clinicopathological significance of Aminopeptidase N/CD13 expression in human gastric carcinoma.
人胃癌中氨基肽酶 N/CD13 表达的临床病理意义。
DOI: --
发表时间: 2005
期刊: Hepato-gastroenterol. (in press)
影响因子: --
作者: [Kawamura, J. et al.]
通讯作者: J. et al.
23
    Inhibition of metastasis and tetraspanin expression by the human monoclonal antibody directed to CD151 and RNA interference
    • 批准号:
      19390369
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.23万
    • 财政年份:
      2007
    • 负责人:
      MIYAKE Masayuki
    • 依托单位:
    Analysis of the function of TM4SF complex and lung cancer gene therapy based on using this complex.
    • 批准号:
      14370421
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.02万
    • 财政年份:
      2002
    • 负责人:
      MIYAKE Masayuki
    • 依托单位:
    Suppression of metastasis due to regulation of PETA3/CD151
    • 批准号:
      12470280
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.41万
    • 财政年份:
      2000
    • 负责人:
      MIYAKE Masayuki
    • 依托单位:
    Cancer Gene Therapy with Adenovirally or Immunogene TM4SF
    • 批准号:
      10557115
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $8.0万
    • 财政年份:
      1998
    • 负责人:
      MIYAKE Masayuki
    • 依托单位:
    国内基金
    海外基金
    AAH羟化酶活性介导肝内胆管癌的经淋巴途径转移及分子机制